These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 29789630

  • 1. Preclinical evaluation of ribociclib and its synergistic effect in combination with alpelisib in non-keratinizing nasopharyngeal carcinoma.
    Wong CH, Ma BBY, Hui CWC, Lo KW, Hui EP, Chan ATC.
    Sci Rep; 2018 May 22; 8(1):8010. PubMed ID: 29789630
    [Abstract] [Full Text] [Related]

  • 2. Preclinical evaluation of the dual mTORC1/2 inhibitor sapanisertib in combination with cisplatin in nasopharyngeal carcinoma.
    Zhang J, Jiang Y, Yu Y, Li J.
    Eur J Pharmacol; 2022 Jan 15; 915():174688. PubMed ID: 34883074
    [Abstract] [Full Text] [Related]

  • 3. Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo.
    Xiong Y, Li T, Assani G, Ling H, Zhou Q, Zeng Y, Zhou F, Zhou Y.
    Biomed Pharmacother; 2019 Apr 15; 112():108602. PubMed ID: 30784916
    [Abstract] [Full Text] [Related]

  • 4. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
    Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sánchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, Dugger TC, Wei W, Knudsen ES, Arteaga CL.
    Cancer Res; 2017 May 01; 77(9):2488-2499. PubMed ID: 28249908
    [Abstract] [Full Text] [Related]

  • 5. Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma.
    Wood AC, Krytska K, Ryles HT, Infarinato NR, Sano R, Hansel TD, Hart LS, King FJ, Smith TR, Ainscow E, Grandinetti KB, Tuntland T, Kim S, Caponigro G, He YQ, Krupa S, Li N, Harris JL, Mossé YP.
    Clin Cancer Res; 2017 Jun 01; 23(11):2856-2868. PubMed ID: 27986745
    [Abstract] [Full Text] [Related]

  • 6. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
    Reiter FP, Denk G, Ziesch A, Ofner A, Wimmer R, Hohenester S, Schiergens TS, Spampatti M, Ye L, Itzel T, Munker S, Teufel A, Gerbes AL, Mayerle J, De Toni EN.
    Cell Oncol (Dordr); 2019 Oct 01; 42(5):705-715. PubMed ID: 31250364
    [Abstract] [Full Text] [Related]

  • 7. Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer.
    Yuan Y, Wen W, Yost SE, Xing Q, Yan J, Han ES, Mortimer J, Yim JH.
    Sci Rep; 2019 May 17; 9(1):7509. PubMed ID: 31101835
    [Abstract] [Full Text] [Related]

  • 8. XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.
    Ji J, Yu Y, Li ZL, Chen MY, Deng R, Huang X, Wang GF, Zhang MX, Yang Q, Ravichandran S, Feng GK, Xu XL, Yang CL, Qiu MZ, Jiao L, Yang D, Zhu XF.
    Theranostics; 2018 May 17; 8(6):1494-1510. PubMed ID: 29556337
    [Abstract] [Full Text] [Related]

  • 9. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
    Li T, Xiong Y, Wang Q, Chen F, Zeng Y, Yu X, Wang Y, Zhou F, Zhou Y.
    Artif Cells Nanomed Biotechnol; 2019 Dec 17; 47(1):4001-4011. PubMed ID: 31588803
    [Abstract] [Full Text] [Related]

  • 10. Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All).
    Bortolozzi R, Mattiuzzo E, Trentin L, Accordi B, Basso G, Viola G.
    Biochem Pharmacol; 2018 Jul 17; 153():230-241. PubMed ID: 29408328
    [Abstract] [Full Text] [Related]

  • 11. Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck.
    van Caloen G, Schmitz S, El Baroudi M, Caignet X, Pyr Dit Ruys S, Roger PP, Vertommen D, Machiels JP.
    Mol Cancer Ther; 2020 Mar 17; 19(3):777-789. PubMed ID: 31924739
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma.
    Chen D, Sun X, Zhang X, Cao J.
    Biomed Res Int; 2020 Mar 17; 2020():9525207. PubMed ID: 32626773
    [Abstract] [Full Text] [Related]

  • 13. Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma.
    Wong CH, Loong HH, Hui CW, Lau CP, Hui EP, Ma BB, Chan AT.
    Invest New Drugs; 2013 Dec 17; 31(6):1399-408. PubMed ID: 23975511
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo.
    Huang Y, Tian Y, Zhao Y, Xue C, Zhan J, Liu L, He X, Zhang L.
    Cancer Commun (Lond); 2018 May 03; 38(1):15. PubMed ID: 29764490
    [Abstract] [Full Text] [Related]

  • 15. A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer.
    Lee HJ, Lee WK, Kang CW, Ku CR, Cho YH, Lee EJ.
    Cancer Lett; 2018 Mar 28; 417():131-140. PubMed ID: 29306020
    [Abstract] [Full Text] [Related]

  • 16. Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma.
    Hsu CL, Lui KW, Chi LM, Kuo YC, Chao YK, Yeh CN, Lee LY, Huang Y, Lin TL, Huang MY, Lai YR, Yeh YM, Fan HC, Lin AC, Lu YJ, Hsieh CH, Chang KP, Tsang NM, Wang HM, Chang AY, Chang YS, Li HP.
    J Exp Clin Cancer Res; 2018 Sep 20; 37(1):233. PubMed ID: 30236142
    [Abstract] [Full Text] [Related]

  • 17. Activation of sterol regulatory element-binding protein 1 (SREBP1)-mediated lipogenesis by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) promotes cell proliferation and progression of nasopharyngeal carcinoma.
    Lo AK, Lung RW, Dawson CW, Young LS, Ko CW, Yeung WW, Kang W, To KF, Lo KW.
    J Pathol; 2018 Oct 20; 246(2):180-190. PubMed ID: 29968360
    [Abstract] [Full Text] [Related]

  • 18. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.
    Wang Y, Wang Y, Fan X, Song J, Wu H, Han J, Lu L, Weng X, Nie G.
    Biochem Biophys Res Commun; 2018 Sep 10; 503(3):1214-1220. PubMed ID: 30017199
    [Abstract] [Full Text] [Related]

  • 19. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y, Zhang J, Tian Y, Xue C, Hu Z, Zhang L.
    Drug Des Devel Ther; 2015 Sep 10; 9():4897-907. PubMed ID: 26345996
    [Abstract] [Full Text] [Related]

  • 20. Pectolinarigenin Suppresses the Tumor Growth in Nasopharyngeal Carcinoma.
    Wang C, Cheng Y, Liu H, Xu Y, Peng H, Lang J, Liao J, Liu H, Liu H, Fan J.
    Cell Physiol Biochem; 2016 Sep 10; 39(5):1795-1803. PubMed ID: 27744436
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.